Serum HER-2 concentration is associated with insulin resistance and decreases after weight loss

Nutrition and Metabolism

Volumn 7, Issue , 2010, Pages

  Fernndez Real, José Manuel ^a,b   Menendez, Javier A ^b,c   Frühbeck, Gema ^d   Moreno Navarrete, José María ^a,b   Vazquez Martín, Alejandro ^b,c   Ricart, Wifredo ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b HOSPITAL JOSEP TRUETA   (Spain)

^c CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

ARTICLE; BODY FAT; BODY MASS; COMORBIDITY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

EID: 77949766943     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-7-14     Document Type: Article

References (40)

1. Diabetes mellitus and risk of breast cancer: a meta-analysis. SC Larsson CS Mantzoros A Wolk, Int J Cancer 2007 121 856 862 10.1002/ijc.22717 17397032
2. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. SC Larsson N Orsini A Wolk, J Natl Cancer Instit 2005 97 1679 1687
3. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. E Friberg N Orsini CS Mantzoros A Wolk, Diabetologia 2007 50 1365 1374 10.1007/s00125-007-0681-5 17476474
4. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. HB El-Serag H Hampel F Javadi, Clin Gastroenterol Hepatol 2006 4 369 380 10.1016/j.cgh.2005.12.007 16527702
5. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. R Huxley A Ansary-Moghaddam A Berrington de Gonzalez F Barzi M Woodward, Br J Cancer 2005 92 2076 2083 10.1038/sj.bjc.6602619 15886696
6. Long-term All-Cause Mortality in Cancer Patients With Preexisting Diabetes Mellitus A Systematic Review and Meta-analysis. BB Barone HC Yeh CF Snyder, et al. JAMA 2008 300 2754 2764 10.1001/jama.2008.824 19088353
7. Effect of insulin on cell cycle progression in MCF-7 breast cancer cells. Direct and potentiating influence. J Chappell JW Leitner S Solomon I Golovchenko ML Goalstone B Draznin, J Biol Chem 2001 276 38023 38028 10.1074/jbc.M106008200 11500498
8. Mitogenic stimulation of human breast cancer cells in a growth factor-defined medium: synergistic action of insulin and estrogen. B Van der Burg GR Rutteman MA Blankenstein SW de Laat EJ van Zoelen, J Cell Physiol 1988 134 101 108 10.1002/jcp.1041340112 3275677
9. Insulin receptors in breast cancer: biological and clinical role. V Papa A Belfiore, J Endocrinol Invest 1996 19 324 333 8796343
10. Insulin receptors in breast cancer. A Belfiore L Frittitta A Costantino, et al. Ann NY Acad Sci 1996 784 173 188 10.1111/j.1749-6632.1996.tb16235.x 8651567
11. Serum C-peptide levels and breast cancer risk: results from the European Prospective Investigation into Cancer and Nutrition [EPIC]. M Verheus PH Peeters S Rinaldi, et al. Int J Cancer 2006 119 659 667 10.1002/ijc.21861 16572422
12. Hyperinsulinaemia and increased risk of breast cancer: findings from the British Women's Heart and Health Study. DA Lawlor GD Smith S Ebrahim, Cancer Causes Control 2004 15 267 275 10.1023/B:CACO.0000024225.14618.a8 15090721
13. Insulin, insulin-like growth factor-I and breast cancer risk in Japanese women. K Hirose T Toyama H Iwata T Takezaki N Hamajima K Tajima, Asian Pac J Cancer Prev 2003 4 239 246 14507245
14. Population-based, case-control study of blood C-peptide level and breast cancer risk. G Yang G Lu F Jin, et al. Cancer Epidemiol Biomarkers Prev 2001 10 1207 1211 11700270
15. Fasting glucose is a risk factor for breast cancer: a prospective study. P Muti T Quattrin BJ Grant, et al. Cancer Epidemiol Biomarkers Prev 2002 11 1361 1368 12433712
16. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. PJ Mink E Shahar WD Rosamond AJ Alberg AR Folsom, Am J Epidemiol 2002 156 349 352 10.1093/aje/kwf050 12181105
17. Serum insulin-like growth factor-I and breast cancer. P Toniolo PF Bruning A Akhmedkhanov, et al. Int J Cancer 2000 88 828 832 10.1002/1097- 0215(20001201)88:5<828::AID-IJC22>3.0.CO;2-8 11072255
18. Prospective study of IGF-I, IGF-binding proteins, and breast cancer risk, in northern and southern Sweden. R Kaaks E Lundin S Rinaldi, et al. Cancer Causes Control 2002 13 307 316 10.1023/A:1015270324325 12074500
19. Insulin and insulin-like growth factor signalling in neoplasia. M Pollack, Nature Rev Cancer 2008 8 915 928 10.1038/nrc2536
20. Insulin-like growth factor [IGF]-I, IGF binding protein-3, and breast cancer risk: eight years on. AG Renehan M Harvie A Howell, Endocr Relat Cancer 2006 13 273 278 10.1677/erc.1.01219 16728563
21. Characterization of the binding of 125-I-labeled epidermal growth factor to human fibroblasts. G Carpenter KJ Lembach MM Morrison S Cohen, J Biol Chem 1975 250 4297 4304 1126952
22. Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. J Schlessinger, Cell 2002 110 669 672 10.1016/S0092-8674(02)00966-2 12297041
23. ErbB receptors and EGF-like ligands: cell lineage determination through combinatorial signaling. R Pinkas-Kramarski I Alroy Y Yarden, J Mammary Gland Biol Neoplasia 1997 2 97 108 10.1023/A:1026343528967 10882296
24. Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cells. J Codony-Servat J Albanell JC Lopez-Talavera J Arribas J Baselga, Cancer Res 1999 59 1196 1201 10096547
25. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. DJ Slamon GM Clark SG Wong WJ Levin A Ullrich WL McGuire, Science 1987 235 177 182 10.1126/science.3798106 3798106
26. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer. H Yamauchi V Stearns DF Hayes, J Clin Oncol 2001 9 2334 2356
27. The antidiabetic drug metformin suppresses HER2 [erbB-2] oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. A Vazquez-Martin C Oliveras-Ferraros JA Menendez, Cell Cycle 2009 8 88 96 19106626
28. Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance. JM Fernandez-Real M Broch W Ricart, et al. Diabetes 1998 47 1757 1762 10.2337/diabetes.47.11.1757 9792545
29. Plasma osteopontin levels and expresián in adipose tissue in obesity. J Gámez-Ambrosi V Cataln B Ramírez, et al. J Clin Endocrinol Metab 2007 92 3719 27 10.1210/jc.2007-0349 17595250
30. Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer. HJ Huang P Neven M Drijkoningen, et al. Ann Oncol 2005 16 1755 61 10.1093/annonc/mdi364 16085689
31. Hsp90, not Grp94, regulates the intracellular trafficking and stability of nascent ErbB2. W Xu EG Mimnaugh JS Kim JB Trepel LM Neckers, Cell Stress Chaperones 2002 7 91 96 10.1379/1466-1268(2002)007<0091:HNGRTI>2.0.CO;2 11892991
32. Epidermal growth factor receptor defects in leprechaunism. A multiple growth factor-resistant syndrome. SS Reddy CR Kahn, J Clin Invest 1989 84 1569 76 10.1172/JCI114334 2808704
33. Decreased levels of hepatic epidermal growth factor receptors in obese hyperglycemic rodents. PJ Blackshear DJ Stumpo EA Kennington, et al. J Biol Chem 1987 262 12356 12364 3624263
34. Decreased binding of epidermal growth factor in placentas from streptozotocin-diabetic rats. JF Sissom WK Stenzel JB Warshaw, J Clin Invest 1987 80 242 247 10.1172/JCI113054 3496364
35. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. A Vazquez-Martin R Colomer J Brunet R Lupu JA Menendez, Cell Prolif 2008 41 59 85 18211286
36. Effect of tumor necrosis factor-alpha on the phosphorylation of tyrosine kinase receptors is associated with dynamic alterations in specific protein-tyrosine phosphatases. F Ahmad BJ Goldstein, J Cell Biochem 1997 64 117 127 10.1002/(SICI)1097-4644(199701)64:1<117::AID-JCB14>3.0.CO;2-I 9015760
37. Neuregulin signaling on glucose transport in muscle cells. C Canto E Suarez JM Lizcano, et al. J Biol Chem 2004 279 12260 12268 10.1074/jbc. M308554200 14711829
38. A novel role of neuregulin in skeletal muscle: neuregulin stimulates glucose uptake, glucose transporter translocation, and transporter expression in muscle cells. E Suarez D Bach J Cadefau M Palacin A Zorzano A Guma, J Biol Chem 2001 276 18257 18264 10.1074/jbc.M008100200 11278386
39. Neuregulins mediate calcium-induced glucose transport during muscle contraction. C Canto AV Chibalin BR Barnes, et al. J Biol Chem 2006 281 21690 21697 10.1074/jbc.M600475200 16740635
40. Betacellulin-delta4, a novel differentiation factor for pancreatic beta-cells, ameliorates glucose intolerance in streptozotocin-treated rats. T Ogata AJ Dunbar Y Yamamoto Y Tanaka M Seno I Kojima, Endocrinology 2005 146 4673 4681 10.1210/en.2005-0456 16081630